Oramed Pharmaceuticals
ORMP
93 hedge funds and large institutions have $119M invested in Oramed Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 39 increasing their positions, 14 reducing their positions, and 7 closing their positions.
257% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 7
179% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 14
132% more capital invested
Capital invested by funds: $51.2M → $119M (+$67.6M)
81% more call options, than puts
Call options by funds: $11.1M | Put options by funds: $6.13M
24% more funds holding
Funds holding: 75 → 93 (+18)
4.41% more ownership
Funds ownership: 12.24% → 16.65% (+4.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$12.7M |
| 2 |
BlackRock
New York
|
+$2.79M |
| 3 |
State Street
Boston,
Massachusetts
|
+$2.32M |
| 4 |
Calamos Advisors
Naperville,
Illinois
|
+$2.25M |
| 5 |
JC
Jetstream Capital
Brentwood,
Tennessee
|
+$2.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.25M |
| 2 |
JSMC
Jess S. Morgan & Co
Los Angeles,
California
|
-$1.85M |
| 3 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
-$971K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$434K |
| 5 |
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
|
-$350K |
ORMP Hedge Fund Activity: Q3 2021 in Review
93 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q3 2021, worth a combined $119M — up 132% from $51.2M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ORMP positions and 7 closed out — a net gain of 18 holders — while 39 added to existing stakes and 14 trimmed.
The largest buyer was Invesco, adding an estimated $12.7M. The largest seller was Millennium Management, cutting an estimated $2.25M.
- 93 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q3 2021, up from 75 in Q2 2021.
- Funds reported $119M of Oramed Pharmaceuticals stock for Q3 2021, up 132% quarter-over-quarter.
- 25 funds opened new Oramed Pharmaceuticals positions in Q3 2021 and 7 closed out, a net change of +18 holders.
- The largest Oramed Pharmaceuticals buyer in Q3 2021 was Invesco, an estimated $12.7M added.
- The largest Oramed Pharmaceuticals seller in Q3 2021 was Millennium Management, an estimated $2.25M sold.
Based on aggregated 13F filings for Q3 2021.